Effects of hepatitis C virus infection on the pharmacokinetics of ritonavir-boosted atazanavir in HIV-1-infected patients

Author： Di Biagio Antonio  

Publisher： Springer Publishing Company

ISSN： 1341-321X

Source： Journal of Infection and Chemotherapy, Vol.18, Iss.4, 2012-08, pp. : 587-590

Disclaimer: Any content in publications that violate the sovereignty, the constitution or regulations of the PRC is not accepted or approved by CNPIEC.

Previous Menu Next

Abstract

Related content

Randomized phase 3 trial of ombitasvir/paritaprevir/ritonavir for hepatitis C virus genotype 1b–infected Japanese patients with or without cirrhosis

By  

HEPATOLOGY, Vol. 270-9139, Iss. 4, 2015-10 ,pp. : 1037-1046

John Wiley & Sons Inc

Access to resources Recommend Favorite

Randomized phase 3 trial of ombitasvir/paritaprevir/ritonavir for hepatitis C virus genotype 1b–infected Japanese patients with or without cirrhosis

By  

HEPATOLOGY, Vol. 62, Iss. 4, 2015-10 ,pp. : 1037-1046

John Wiley & Sons Inc

Access to resources Recommend Favorite

Ritonavir-boosted protease inhibitors in HIV therapy

By Hull Mark W.   Montaner Julio S. G.  

Annals of Medicine, Vol. 43, Iss. 5, 2011-08 ,pp. : 375-388

Informa Healthcare

Access to resources Recommend Favorite

Real‐world effectiveness and safety of paritaprevir/ritonavir, ombitasvir, and dasabuvir with or without ribavirin for patients with chronic hepatitis C virus genotype 1b infection in Taiwan

By  

JOURNAL OF GASTROENTEROLOGY AND HEPATOLOGY, Vol. 33, Iss. 3, 2018-03 ,pp. : 710-717

John Wiley & Sons Inc

Access to resources Recommend Favorite

Randomized trial of interferon‐ and ribavirin‐free ombitasvir/paritaprevir/ritonavir in treatment‐experienced hepatitis C virus–infected patients

By  

HEPATOLOGY, Vol. 61, Iss. 5, 2015-05 ,pp. : 1523-1532

John Wiley & Sons Inc

Access to resources Recommend Favorite